Avalyn Pharma Prices Upsized IPO at $18, Targeting $300M

Avalyn Pharma Confirms IPO Pricing and Upsized Offering

Avalyn Pharma Inc. has officially announced the pricing of its upsized initial public offering. The company will issue 16,666,667 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from this offering are anticipated to reach $300 million, before accounting for underwriting discounts and other associated expenses.

Company Profile and Market Debut Details

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled treatments for severe and rare respiratory diseases. Its primary programs include AP01 and AP02, which are currently in global Phase 2 trials for fibrotic lung diseases. The company is also developing AP03, a combination therapy platform. The offering was managed by a team of joint book-runners including Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities.

Economic Impact and Market Outlook

The successful pricing of this upsized IPO indicates strong investor confidence in Avalyn's pipeline and the broader biopharmaceutical sector. The capital raised is expected to fund the advancement of its clinical trials. Avalyn's shares are set to begin trading on the Nasdaq Global Select Market on April 30, 2026, under the ticker symbol 'AVLN'. The offering is projected to close on May 1, 2026, contingent upon customary closing conditions.

Summary

This $300 million offering marks a significant financial milestone for Avalyn Pharma, providing substantial capital to advance its research and development of novel respiratory therapies. Market participants will be closely watching the stock's performance upon its Nasdaq debut to gauge investor sentiment and the company's future valuation.

FAQ

Q: What is the official IPO price for Avalyn Pharma shares?
A: The initial public offering price is set at $18.00 per share.

Q: How much capital does Avalyn Pharma expect to raise?
A: The company expects to generate gross proceeds of $300 million from the offering.

Q: When will Avalyn Pharma stock be available for trading?
A: The stock is expected to start trading on the Nasdaq under the ticker 'AVLN' on April 30, 2026.

Source: Investing.com